gutflix
GI learning, personalised

Summary

REFRACTORY GUT SWEET SYNDROME TREATED WITH ADALIMUMAB

Wee-Chian Lim

UEG Week Copenhagen 2023 | Poster

Small Intestine & Nutrition

October 15, 2023

A case report describes successful treatment of recalcitrant gut Sweet Syndrome with a novel combination of Adalimumab and Methotrexate after failure of conventional immunosuppressive therapy.

KEY POINTS

- A 50-year-old postmenopausal female with quiescent cutaneous Sweet Syndrome presented with symptomatic iron deficiency anaemia and ileal ulcers with dense neutrophil infiltrates but no histological evidence of inflammatory bowel disease.
- The patient remained refractory to conventional immunosuppressive agents including Azathioprine and Methotrexate monotherapy, with persistent ulcers, abdominal pain, weight loss, and anaemia.
- Treatment with Adalimumab combined with Methotrexate (to reduce immunogenicity) resulted in complete ulcer healing and resolution of symptoms at five months, with successful tapering of Prednisolone and Methotrexate.
- The authors suggest gut Sweet Syndrome should be considered when gut ulcers lack histological features of inflammatory bowel disease, and that anti-TNF therapy may be an alternative in recalcitrant cases.
- This case report may be of interest to gastroenterologists and rheumatologists managing rare neutrophilic disorders refractory to standard immunosuppression.

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/27d9bda6-743b-11ee-a0de-0242ac140004

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.